Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

About Us
We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

Our Technology
We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

Our Products

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Fraudulent attempts to use Xbrane's name

We want to inform our customers, partners, and other stakeholders that we have become aware of fraudulent attempts to use Xbrane’s name, particularly fake recruitment services. We take the security of our customers and business relationships very seriously and, therefore, emphasize the importance of remaining vigilant.

Please note that Xbrane does not engage in external advertisements for recruitment purposes. Our official recruitment communication channels are limited to our website (https://www.xbrane.com), email addresses ending with @xbrane.com, and our company page on LinkedIn (https://www.linkedin.com/company/xbrane-bioscience-ab).

Interview with CEO Martin Åmark, October 2023

At Xbrane Biopharma

Press Releases

27 Sep 2024

Xbrane provides update from Scientific Advice with US FDA on Xdivane™ (Opdivo® biosimilar candidate)

28 Aug 2024

Xbrane Biopharma releases Interim Report for January-June 2024

23 Aug 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2024 on August 28, 2024

12 Aug 2024

Xbrane provides update on the ongoing out-licensing of Xdivane™ (nivolumab biosimilar candidate) and XB003 (Cimzia® biosimilar candidate) and its financial position

01 Aug 2024

Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA®

16 Jul 2024

Xbrane provides update on its development portfolio

08 Jul 2024

Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate

22 May 2024

Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® – and run an active partnering process

16 May 2024

Xbrane Biopharma releases Interim Report for January-March 2024